Dan McCoy, MD
about 1 month ago
This is big news in a big industry. It may be time for companies to reevaluate drug selection regarding coverage for particular weight loss drugs. Especially as more data emerges related to the effectiveness of these drugs. What do you think? medcitynews.com/2024/12/eli-lilly-zepbound-wegovy-head-to-head-trial-weight-loss-obesity-tirzepatide-lly/?utm_campaign=MCN BioPharma&utm_medium=email&_hsenc=p2ANqtz-87IE3JXxZT2fi8RrxX18AQgT3VGY6U8-5QGnuzWl5pKgHwbR9dvtB9Dn47-Zt1dvxhBgFN4qplrYmhvky6lFEgeHfBjkVyvRTbXMt2KLxhCtSV0fc&_hsmi=337052378&utm_content=337052378&utm_source=hs_email
Page created with TweetHunter
Write your own